Fact CheckerSign in

NCT07747701Recruiting

Ultra-early Identification of Futile Recanalization After Reperfusion Therapy in Acute Ischemic Stroke Based on Cerebral Autoregulation Monitoring

Ultra-early Identification of Futile Recanalization After Reperfusion Therapy in Acute Ischemic Stroke Based on Cerebral Autoregulation Monitoring: a Multicenter, Prospective, Interventional Study

Source: ClinicalTrials.gov · Last updated 13 Oct 2026

Brief summary (registry, in English)

This multicenter, prospective, and interventional diagnostic accuracy study enrolls patients undergoing thrombectomy with intraoperative cerebral autoregulation monitoring and follows them up at predefined time points up to 90 days post-enrollment.This study aims to evaluate a monitoring system based on cerebral autoregulation function and explore its predictive value for adverse neurological outcomes at the ultra-early stage following mechanical thrombectomy.

Status (registry)
Recruiting
Study type
Interventional
Enrollment
227 (estimated)
First submitted
31 Jul 2026
Start date
31 Jul 2026
Primary completion date
31 Jan 2027
Lead sponsor
Beijing Shijitan Hospital, Capital Medical University
Diseases
Stroke
NCT number
NCT07747701

What you commit to

  • Study type: Interventional
  • Planned participants: 227
  • From 31 Jul 2026 to the primary completion date, 31 Jan 2027
  • 4 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Severe alcohol dependence or drug dependence.
  • Participation in another clinical drug or device study within the past 30 days.

Other illness

  • Pre-procedural baseline imaging showing significant intracranial hemorrhagic transformation, intracranial arterial dissection, large chronic cerebral infarction, or intracranial metastasis from malignant tumors.
  • Known history of carotid sinus hypersensitivity syndrome, severe autonomic dysfunction, sick sinus syndrome, high-grade atrioventricular conduction block, or other malignant arrhythmias.
  • Refractory malignant hypertensive crisis (systolic blood pressure persistently ≥ 200 mmHg despite standardized intravenous antihypertensive therapy, or hemodynamic instability with shock).
  • Known severe allergy to contrast agents or anesthetic drugs, or contraindications to antiplatelet/anticoagulation therapy.
  • Severe systemic active infection, multiple organ failure, or expected survival \< 6 months.
  • Heart failure with NYHA class \> II, or persistent systolic blood pressure \< 100 mmHg.
  • Central nervous system infection or intracranial tumor.
  • Cognitive impairment or psychiatric disorders that may affect follow-up assessments.
  • Local skin damage or other conditions preventing proper placement of monitoring electrodes.
  • Severe agitation or other conditions that interfere with data acquisition.
  • Any other condition judged by investigators to potentially affect study results.

Lab values

  • Severe hepatic or renal dysfunction (ALT/AST \> 3× upper limit of normal; estimated glomerular filtration rate \< 30 mL/min) or severe coagulation disorders (platelet count \< 40 × 10⁹/L, APTT \> 50 s, INR \> 3.0).
  • Blood glucose \< 2.7 mmol/L or \> 22.2 mmol/L.

Other

  • Any degree of stenosis, plaque, dissection, severe tortuosity, or imaging evidence of unstable/vulnerable plaque in the target-side or bilateral common carotid artery or the origin of the internal carotid artery.
  • Unstable vital signs.
  • Pregnant or breastfeeding women.

Who the study is looking for

  • Age ≥ 18
  • Diagnosis of acute ischemic stroke caused by anterior circulation large vessel occlusion (intracranial internal carotid artery or M1 segment of the middle cerebral artery).
  • National Institutes of Health Stroke Scale (NIHSS) score ≥ 6 at presentation.
  • Pre-stroke modified Rankin Scale (mRS) score ≤ 1.
  • Symptom onset ≤ 24 hours.
  • For patients with symptom onset within 6 hours: ASPECTS ≥ 6; for patients with symptom onset between 6 and 24 hours: age ≤ 80 years and ASPECTS ≥ 3.
  • Underwent mechanical thrombectomy and achieved successful recanalization (mTICI 2b-3).
  • Patient or legally authorized representative provides written informed consent.

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (4)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Beijing Shijitan Hospital, Capital Medical University
Coordinator of this site? Confirm its status
BeijingChinaRecruiting
Central Hospital of Dalian University of Technology (Dalian Municipal Central Hospital)
Coordinator of this site? Confirm its status
DalianChinaRecruiting
The First Affiliated Hospital of Harbin Medical University
Coordinator of this site? Confirm its status
HeilongjiangChinaNot yet recruiting
Weifang People's Hospital Affiliated to Weifang Medical University
Coordinator of this site? Confirm its status
ShandongChinaRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.